A citrus-derived flavonoid packed inside chitosan nanoparticles has shown a striking double benefit in mice carrying Ehrlich ascites carcinoma: it shrank tumor burden and, at the same time, protected the kidneys from the secondary damage that aggressive tumors inflict. The study, published in Medical Oncology by a team led by Ahmad Najem Alshammari of Northern Border University in Saudi Arabia, offers the first evidence that diosmin delivered via chitosan nanoparticles can simultaneously act as an anticancer agent and a renoprotective compound in a living tumor model. The work matters because kidney injury in cancer patients is a common and dangerous complication, driven both by tumor biology and by the toxicity of chemotherapy drugs, and current options for protecting the kidneys remain limited.
Diosmin is a naturally occurring flavonoid found predominantly in citrus fruits and has long been used clinically, most famously in formulations for venous disorders such as varicose veins and hemorrhoids. Over the past decade, laboratory studies have accumulated suggesting that the molecule has much broader potential: it has been shown to blunt oxidative damage in models of doxorubicin-induced nephrotoxicity, gentamicin kidney injury, arsenite toxicity, and methotrexate-related organ damage. The catch has always been bioavailability. Diosmin is poorly soluble in water, which limits how much of the compound reaches target tissues when administered in its free form. That pharmacological weakness is precisely what the new study set out to overcome by loading the flavonoid into chitosan nanoparticles, a biocompatible polymer carrier derived from shellfish chitin that is increasingly popular in nanomedicine for its stability, mucoadhesive properties, and ability to sustain drug release.
The experimental design was straightforward but thorough. Sixty female Swiss albino mice were divided into six groups: healthy controls, animals given free diosmin alone, animals given the nanoparticle formulation alone, animals bearing Ehrlich ascites carcinoma without treatment, and two tumor-bearing groups treated with either free diosmin or the nanoparticle version. Both formulations were administered at a dose of 100 milligrams per kilogram per day for twenty days, with or without tumor induction. Ehrlich ascites carcinoma is a widely used preclinical model in which tumor cells proliferate in the peritoneal cavity, causing progressive abdominal swelling, weight gain, and systemic illness that mirrors several features of advanced malignancy in humans, including paraneoplastic organ damage.
The results on tumor burden were unambiguous. Mice receiving the nanoparticle formulation showed significantly lower body weight gain, reduced abdominal circumference, smaller tumor volumes, and lower counts of viable tumor cells than untreated tumor-bearing animals, and the effect was consistently stronger than that achieved with free diosmin. Treated animals also survived longer. According to the authors, the nanoparticle delivery system likely enhanced therapeutic performance through improved stability and sustained-release properties, allowing the flavonoid to remain active in circulation for longer periods and at more effective concentrations than the free compound.
What elevates the study beyond a simple drug-delivery demonstration is its focus on the kidneys. Tumor-bearing mice that received the nanoparticle treatment showed markedly improved renal function markers, including reduced urea and creatinine levels and better-preserved electrolyte balance. This indicates that as tumor progression slowed, the secondary renal injury that accompanies advanced ascites disease was attenuated as well. Histopathological examination of kidney tissue and ultrastructural analysis at the electron microscopy level confirmed that the nanoparticle formulation provided superior structural protection compared with free diosmin, preserving the delicate architecture of the renal tubules and glomeruli far more effectively.
At the molecular level, the researchers traced the protective effect to two interconnected signaling axes. The first is the Nrf2 pathway, the master regulator of cellular antioxidant defense. Under oxidative stress, the transcription factor Nrf2 migrates to the nucleus and switches on genes such as heme oxygenase-1 (HO-1) and NQO1, which manufacture enzymes that neutralize reactive oxygen species. In the treated mice, the Nrf2/HO-1/NQO1 pathway was clearly activated, and this translated into measurable biochemical changes: the activities of superoxide dismutase, catalase, and glutathione peroxidase all increased, levels of reduced glutathione rose, and malondialdehyde, a standard marker of lipid peroxidation and oxidative membrane damage, fell. In other words, the nanoparticle treatment re-armed the kidney’s intrinsic antioxidant machinery at exactly the moment the tumor environment was overwhelming it.
The second axis involves inflammation and programmed cell death. The treatment down-regulated genes controlling inflammatory pathways, including Tgfb1, Nfkb1, and Il6, thereby suppressing the TGF-β, NF-κB, and interleukin-6 signaling cascades that drive both tumor progression and inflammatory kidney damage. At the same time, the formulation shifted the apoptotic balance within kidney tissue: expression of the pro-apoptotic markers Bax and caspase-3 decreased, while the anti-apoptotic protein Bcl-2 increased. This dual suppression of inflammatory signaling and apoptotic execution suggests that the flavonoid protects renal cells not merely by mopping up free radicals but by intervening upstream, at the level of the transcriptional programs that decide whether stressed cells spiral into inflammation and death.
To bolster the experimental findings, the team also performed molecular docking simulations, an in silico technique that models how a small molecule fits into the binding pockets of target proteins. The docking results provided supportive evidence that diosmin can interact with Nrf2, NF-κB, caspase-3, and TGF-β-related molecular targets, the very proteins implicated in the oxidative stress, inflammatory, and apoptotic pathways the study measured. While docking studies are computational and cannot substitute for direct binding experiments, they offer a plausible structural rationale for the pleiotropic effects observed in the animals and help explain why a single flavonoid can touch so many nodes of the damage response network simultaneously.
The study is not without limitations that readers should keep in mind. It was conducted entirely in mice, using a single dose and a fixed treatment window, and the Ehrlich ascites model, although valuable, does not recapitulate every feature of human cancers. The authors note that the datasets used and analyzed in the study are available from the corresponding author on reasonable request, and the work was approved by the ethics committee of the Faculty of Applied Health Sciences Technology at October 6 University in Egypt. Translating these findings into human medicine will require dose-ranging studies, pharmacokinetic profiling of the nanoparticle formulation, and eventually clinical trials in cancer patients at risk of renal injury. Still, the convergence of antitumor efficacy, biochemical protection, histological preservation, and mechanistic coherence makes this one of the more complete preclinical demonstrations of nanodelivered flavonoid therapy to date.
The broader significance lies in what the study says about the future of supportive cancer care. Kidney injury in oncology patients arises from a tangle of causes, including tumor-derived inflammatory mediators, oxidative stress, and the nephrotoxicity of chemotherapeutic agents, and it is associated with worse survival and fewer treatment options. A single agent that simultaneously restrains tumor growth and fortifies kidney tissue against oxidative, inflammatory, and apoptotic damage, delivered through a biocompatible and already clinically familiar polymer carrier, represents an appealing strategy. If subsequent research confirms that diosmin-loaded chitosan nanoparticles behave similarly in larger animal models and in humans, the humble citrus flavonoid long relegated to pharmacy shelves for vein disorders could find a second, far more consequential career in oncology, this time wrapped in nanoparticles and aimed at protecting one of the body’s most vulnerable vital organs.
Subject of Research: Nanoparticle-delivered diosmin as a renoprotective and anticancer therapy in Ehrlich ascites carcinoma-bearing mice
Article Title: Nano-Diosmin mitigates EAC-induced renal injury through Nrf2-mediated antioxidant activation and NF-κB-dependent apoptotic suppression
Article References: Alshammari, A. N., Alfawaz, M. S., Oraby, F., Mohamed, A. M., Elmorsy, E. M., Mohamed, S. S. A., Atta, M. M. F., & El-Raghi, A. A. (2026). Nano-Diosmin mitigates EAC-induced renal injury through Nrf2-mediated antioxidant activation and NF-κB-dependent apoptotic suppression. Medical Oncology, 43(11), Article 317. https://doi.org/10.1007/s12032-026-03387-3
Image Credits: AI Generated
DOI: 10.1007/s12032-026-03387-3
Keywords: diosmin, chitosan nanoparticles, Ehrlich ascites carcinoma, kidney injury, Nrf2, NF-κB, oxidative stress, apoptosis, renoprotection, flavonoids, nanomedicine, Medical Oncology
